Introduction
The immune response to influenza vaccines and subsequent protection against virus challenge have been reported in many animal species. Most of the studies were performed many years ago, when Francis (1939) , Fazekas de St Groth and Donnelly (1950) and others observed that inactivated influenza A viruses conferred specific protection to mice subsequently challenged with mouse-adapted influenza virus. Kaye, Dowdle and McQueen (1969) later showed some degree of cross-protection between members of the H2N2 subtype of influenza A virus, when mice were immunized with an inactivated vaccine and then were challenged with mouseadapted strains of various H2N2 influenza A viruses derived from strains which circulated between 1957 and 1965. These studies indicated that influenza A viruses, inactivated by formaldehyde, and given in adequate amounts, would produce an immune response as measured by serum haemagglutinationinhibiting antibodies and by protection against subsequent lethal challenge with the mouse-adapted virus of the same or a closely related strain. Although other animal models have been used to study the immune response to influenza vaccines and infection, the mouse model of pulmonary infection has been used most extensively.
The purpose of the studies described here was two-fold: (1) there have been no reports of viral challenge studies in animal models using the recently developed split-product influenza vaccines which have been licensed in the United States. These vaccines are made by using chemicals which disrupt the virion. The earlier vaccine studies using the mouse model employed vaccines with intact virus particles; and (2) to obtain information in this animal model on the influenza strains which are currently circulating including the A/Port Chalmers/1/73 (H3N2) and B/Hong Kong/5/72 strains.
Materials and methods

Vaccines
Commercially produced licensed vaccines were used in this study. The vaccines were prepared so that they contained a total of at least 1200 chick cell agglutinating units (CCA) of viral antigen per 05 ml when compared to a standard vaccine reference as described by Tauraso, O'Brien and Seligmann (1969) . The vaccines contained at least 700 CCA of the A/Port Chalmers/1/73 antigen and 500 CCA of B/Hong Kong/5/72 antigen per 0 5 ml. Three vaccines were produced as whole virus vaccines, concentrated and purified by rate zonal centrifugation (Reimer et al., 1967) . One vaccine was a whole virus vaccine prepared by column chromatography and two vaccines were split-product preparations, one having been treated with Tween-80 and ether (Cromwell et al., 1969) , the other with tri-N-butyl phosphate (Neurath et al., 1970 ).
Mice
Inbred 3-4-week-old male CFW strain mice purchased from Carworth Farms were inoculated i.p. with 0-5 ml of vaccine diluted in phosphate buffered saline, pH 7-2 (PBS). Groups of fifteen mice each were given 10-1, 10-2 and 10-3 dilutions of the six vaccines tested.
Mouse-adapted influenza viruses
Prototype strains of egg-grown influenza viruses (A/Port Chalmers/1/73 and B/Hong Kong/5/72) were administered intranasally as undiluted allantoic fluid to ten 3-week-old CFW mice. Forty-eight to 72 hr later, three mice were killed; their lungs were homogenized and a 10% suspension was then used to pass the virus to another ten mice. Virus, 0-1 ml, was administered intranasally under ether anaesthesia. The seven remaining mice were observed for survival. This process was repeated serially. When it was observed during this serial passage that a majority of mice died in 1 week with generalized pulmonary consolidation, the lung suspension employed for that mouse passage was inoculated into the allantoic cavity of embryonated eggs to prepare a pool of virus virulent for mice. The harvested fluids were pooled, clarified and used for challenge experiments involving mice. The mouse-adapted virus was characterized by haemagglutination-inhibition (HI) testing with monospecific antisera prepared in chickens, and sera from mice infected with the stock virus were characterized with specific viral haemagglutinating antigens. These (Snedecor and Cochran, 1967) .
Results
The vaccines used in these experiments were coded so that the individuals measuring the serological response and challenge results would not know the identity of the vaccines being tested. Table 1 outlines the vaccines used, their potency as measured in the CCA test, and the type of production process used to make the vaccines. For the sake of consistency and clarity the vaccines are listed as they have been described earlier (Barry, Staton and Mayner, 1974) .
Data presented in Fig. 1 summarize the results of an experiment in which mice were given serial dilutions of each of the vaccines described in Table 1 and were challenged with approximately 30 LD50 of A/Port Chalmers/1/73 mouse-adapted virus 4 weeks after immunization. On the day before challenge, the mice were bled retro-orbitally and the individual sera were used to assay HI antibody. Twenty-six of thirty control mice which had been injected with diluent, died from the mouse virulent virus. All four of the whole virus vaccines induced significant resistance to this challenge dose of mouseadapted virus at the 10-1 dilution of vaccine which contained approximately 70 CCA units of the homotypic A/Port Chalmers antigen, but the two splitproduct vaccines (ET, TBP) did not protect at this dilution. Two of the whole virus vaccines conferred protection against challenge at the higher dilutions Ether treated split-product (ET) 1 -4 Tri-N-butyl phosphate treated split-product than the other vaccines, confirming earlier work from this laboratory (Barry et al., 1974) . This is evident when a comparison is made between the individual split-product vaccines and the other five vaccines, including the four whole virus and the other splitproduct vaccine. None of the whole virus vaccines was significantly less immunogenic than the other five vaccines when they were compared in this fashion.
In Table 3 , the mean antibody titres induced by the split-product vaccines to B/Hong Kong antigen are shown and compared with the antibody response induced by the whole virus vaccines. In most dilutions vaccines ET and TBP produced significantly lower levels of HI antibody than did the other vaccines, and in every dilution they produced lower levels of antibody. Combining the antibody responses in mice given the two split-product vaccines and comparing these results to the antibodies induced by the four whole virus vaccines increased the level of statistical significance of these differences. As noted above in the experiment with A/Port Chalmers virus, none of the whole virus vaccines induced significantly lower antibodies than did the other five vaccines given at any dilution.
The above protection experiments utilized a single challenge dose of virus which killed over 90 % of the control mice. We then performed a study to determine the effect of the dose of challenge virus on protection. A/Port Chalmers/1/73 challenge virus was administered to mice which had been previously immunized with 10-1, 10-2 and 10-3 dilutions of two of the same bivalent vaccines used in the above studies, one a whole virus vaccine (ZP-2) and the other a split-product vaccine (TBP). A summary of the protection results is presented in Table 4 . At the lower challenge doses containing approximately 1 LD50, both vaccines protected; however, with a challenge dose of 10 LD,O the split-product vaccine did not protect at the 10-3 dilution. At the highest challenge dose, only the 10-1 and 10-2 doses of the whole virus vaccine conferred significant protection.
The antibody response in these animals is also shown in Table 4 ; as was demonstrated in the earlier experiments, the whole virus vaccine induced a higher antibody response, and this antibody response was associated with protection against high challenge doses. The split-product vaccine induced a lower antibodyresponse and failed to protect against the highest challenge dose, but it did provide some protection at a lower challenge dose of virus.
Discussion
These results confirm and extend earlier observations made on the immunizing and protective effect of influenza vaccines. The decreased antibody response in mice given split-product vaccines when compared to whole virus vaccines, despite their possessing similar haemagglutinin titres as measured by quantitative CCA testing with a reference, may be due to the fact that mice are immunological virgins for influenza virus. Adequate immunological response on primary exposure to antigen may require the presence of either whole virion, as observed in this study, or the addition of adjuvants as others have reported (Davenport, 1968) .
There have been no reports comparing protection conferred against lethal challenge with these modern influenza vaccines. However, the present study confirms earlier reports which provided evidence that formalin-inactivated whole virus influenza vaccines conferred specific protection against subsequent challenge. Hinz et al. (1972) observed a lower HI antibody response to a Tween-ether-disrupted A/ Aichi/68 vaccine than to vaccine made with intact virus. These workers also found the ether-disrupted vaccine to be less protective than the whole virus vaccine in mouse challenge experiments with the A/Aichi/68 strain. The present data confirm that observation and demonstrate that another type of split-product vaccine is also less immunogenic and less protective than whole virus vaccines in this model.
The correlation between the amount of specific serum haemagglutinating antibodies and protection against subsequent challenge seen in this experimental model system has also been observed in man (Hobson et al., 1972) . There are problems associated with extrapolating from laboratory animal data to man, but the fact that the amount of serum antibody present in mice and man is a reliable indication of protection against influenza infection should be noted. It appears that mice, without prior natural immunological experience with influenza viruses, represent a reasonable laboratory model for immunologically virgin man. Such a circumstance is present when a major shift in both surface antigens occurs, or in young children on initial influenza virus infection. It has not been possible to compare the immunogenic effect of modern highly purified whole and split-product vaccines in immunologically virgin adults because influenza virus N2 neuraminidase antigen has not changed completely since 1957, and the H3 haemagglutinin subtypes have been circulating since 1968; therefore, older children and adults have a broad background ofnatural exposure to these antigens. Thus, immunogenicity studies performed in individuals give evidence for the efficacy of the vaccines being tested against this background of experience but cannot be taken as evidence for vaccine effectiveness in animals or man without prior natural exposure to the same or related strains. Limited studies have been performed in young children with intact or disrupted inactivated influenza vaccines. Some of these studies were performed with older experimental H2N2 vaccines and indicated that split-product vaccines were associated with fewer systemic reactions, but they and their whole virus counterparts were poor immunogens. More recent studies performed with zonally purified whole virus vaccines have indicated adequate immunogenicity, but reported higher rates of clinical reactivity (Wright et al., 1975; Marine and StuartHarris, 1975) . These difficulties encountered in determining the efficacy of influenza vaccines in nonimmune man, along with some of the similarities observed between the degree of protection associated with the antibody levels observed in mice and man, lead to a tentative conclusion that certain splitproduct vaccines, without adjuvant, may be less immunogenic for non-immune individuals. More information is needed on the comparative protective efficacy of split-product and whole virus vaccines in immunologically inexperienced subjects.
